These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9822332)

  • 41. [Proline hydroxylase (hPH) as marker of hepatic fibrosis in beta thalassemia].
    Leonardi S; Avola E; Rapisarda R; La Delfa W; Musumeci S
    Pediatr Med Chir; 1991; 13(3):267-9. PubMed ID: 1658753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical significance of the determination of serum immunoreactive prolyl hydroxylase (SIRPH) in hepatic fibrosis].
    Suzuki H; Suzuki M; Okabe K; Uchikoshi T
    Nihon Shokakibyo Gakkai Zasshi; 1987 Jun; 84(6):1265-71. PubMed ID: 2822984
    [No Abstract]   [Full Text] [Related]  

  • 43. [Differences in changes of two serum markers of hepatic fibrogenesis in acute hepatitis].
    Matsuda Y; Yasuhara M; Takada A
    Nihon Shokakibyo Gakkai Zasshi; 1987 Aug; 84(8):1631-8. PubMed ID: 2826851
    [No Abstract]   [Full Text] [Related]  

  • 44. [Serum type III procollagen N-terminal peptide in patients with collagen diseases].
    Aoki A; Hagiwara E; Atsumi Y; Shirai A; Igarashi T; Narita M; Matsunaga K; Ishigatsubo Y; Tani K; Okubo T
    Ryumachi; 1990 Apr; 30(2):81-4. PubMed ID: 2173157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum prolyl hydroxylase protein in experimental liver cancer.
    Bolarin DM
    Acta Physiol Hung; 1988; 71(1):55-9. PubMed ID: 2839006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis.
    Bettinardi N; Felicetta I; Tomasi PA; Colombo C
    Clin Chem Lab Med; 2003 Mar; 41(3):311-6. PubMed ID: 12705340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolyl hydroxylase activity in liver and serum of rats and human subjects intoxicated by chronic administration of ethanol.
    Pawlicka E; Bańkowski E; Pałka J; Markiewicz W
    Hepatogastroenterology; 1987 Dec; 34(6):243-5. PubMed ID: 2828207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of the measurement of serum procollagen type III N-terminal peptide in the evaluation of liver diseases.
    Collazos J; Díaz F
    Clin Chim Acta; 1994 Jun; 227(1-2):37-43. PubMed ID: 7955420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Expression of type III and IV procollagen, prolyl 4-hydroxylase mRNAs in fibrotic human liver].
    Yamada H; Aida T; Taguchi K; Asano G
    Nihon Rinsho; 1993 Feb; 51(2):423-7. PubMed ID: 8385240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The slow progression of hepatic fibrosis in intrahepatic cholestasis as compared with extrahepatic biliary atresia.
    Shirahase I; Ooshima A; Tanaka K; Inamoto T; Yamamoto E; Ozawa K; Yamabe H
    Eur J Pediatr Surg; 1995 Apr; 5(2):77-81. PubMed ID: 7612587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic liver disease.
    Fabris C; Pirisi M; Falleti E; Soardo G; Gonano F; Bartoli E
    Clin Biochem; 1994 Oct; 27(5):407-12. PubMed ID: 7867219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic prolyl hydroxylase activity in human liver disease.
    McPhie JL
    Hepatogastroenterology; 1980 Aug; 27(4):277-82. PubMed ID: 6259037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis.
    Gabrielli GB; Capra F; Casaril M; Squarzoni S; Tognella P; Dagradi R; De Maria E; Colombari R; Corrocher R; De Sandre G
    Clin Chim Acta; 1997 Sep; 265(1):21-31. PubMed ID: 9352126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factor II (prothrombin) coagulant activity in immunoreactive protein: detection of vitamin K deficiency and liver disease in patients with cystic fibrosis.
    Corrigan JJ; Taussig LM; Beckerman R; Wagener JS
    J Pediatr; 1981 Aug; 99(2):254-7. PubMed ID: 7252687
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of hepatic fibrosis by serum proline and amino-terminal type III procollagen peptide levels in alcoholic patients.
    Tanaka Y; Minato Y; Hasumura Y; Takeuchi J
    Dig Dis Sci; 1986 Jul; 31(7):712-7. PubMed ID: 3720468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Procollagen type III peptide in the assessment of liver fibrosis in children with congenital alpha-1-antitrypsin deficiency.
    Rujner J; Socha J; Janas R; Woźniewicz B
    Mater Med Pol; 1991; 23(4):267-72. PubMed ID: 1842233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoreactive prolyl hydroxylase protein and galactosylhydroxylysyl glucosyltransferase activity in breast tissues and sera of patients with primary breast cancer.
    Bolarin DM
    Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):493-502. PubMed ID: 6304825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased deposition and serum level of type IV collagen in patients with extrahepatic biliary atresia.
    Shirahase I; Ooshima A; Tanaka K; Ozawa K; Yamabe H; Yamamoto T
    J Pediatr Surg; 1993 Jun; 28(6):847-50. PubMed ID: 8392544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation.
    Matsumura Y; Sakaida I; Uchida K; Kimura T; Ishihara T; Okita K
    J Hepatol; 1997 Jul; 27(1):185-92. PubMed ID: 9252094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver calcifications in cystic fibrosis.
    Lykavieris P; Guillot M; Pariente D; Bernard O; Hadchouel M
    J Pediatr Gastroenterol Nutr; 1996 Dec; 23(5):565-8. PubMed ID: 8985846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.